Peter Gaszner

Summary

Affiliation: Plant Protection Institute
Country: Hungary

Publications

  1. ncbi [Clinical observations with aripiprazole in schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet
    Neuropsychopharmacol Hung 8:29-32. 2006
  2. ncbi [Complex therapy of schizophrenia]
    Peter Gaszner
    SE Pszichiatriai es Pszichoterapias Klinika
    Neuropsychopharmacol Hung 11:41-5. 2009
  3. ncbi Clozapine maintenance therapy in schizophrenia
    Peter Gaszner
    National Institute of Psychiatry and Neurology, 1021, Budapest, Huvosvolgyi u 116, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:465-9. 2004
  4. ncbi Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
    Peter Gaszner
    National Institute of Psychiatry and Neurology, H 1021 Huvösvölgyi út 116, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 30:5-14. 2006
  5. ncbi Agranulocytosis during clozapine therapy
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 26:603-7. 2002
  6. ncbi The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 6:210-20. 2004
  7. ncbi [About the curability of schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:39-42. 2005
  8. ncbi Comparison between genes of Alzheimer's disease and brain tissue of others
    Peter Gaszner
    National Institute of Neurology and Psychiatry, Budapest, Hungary
    Neuropsychopharmacol Hung 8:211-4. 2006
  9. ncbi About the menopausal depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 7:208-14. 2005
  10. ncbi [Pharmacovigilance as new direction of research]
    Gabor Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:194-8. 2005

Collaborators

Detail Information

Publications10

  1. ncbi [Clinical observations with aripiprazole in schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet
    Neuropsychopharmacol Hung 8:29-32. 2006
    ..The patients had good compliance with aripiprazol...
  2. ncbi [Complex therapy of schizophrenia]
    Peter Gaszner
    SE Pszichiatriai es Pszichoterapias Klinika
    Neuropsychopharmacol Hung 11:41-5. 2009
    ..Fields of indication: first psychotic episode, acut schizophrenic exacerbation, chronic schizophrenia, the treatment of behavior disorder in dementia, maniac phase of bipolar disorder, treatment of behavioral disorders...
  3. ncbi Clozapine maintenance therapy in schizophrenia
    Peter Gaszner
    National Institute of Psychiatry and Neurology, 1021, Budapest, Huvosvolgyi u 116, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:465-9. 2004
    ..Compliance is good; schizophrenic patients are willing to take this atypical antipsychotic for years on end. Clozapine treatment is associated with a low relapse rate and a favorable safety profile...
  4. ncbi Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
    Peter Gaszner
    National Institute of Psychiatry and Neurology, H 1021 Huvösvölgyi út 116, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 30:5-14. 2006
    ....
  5. ncbi Agranulocytosis during clozapine therapy
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 26:603-7. 2002
    ..These adverse reactions were recognized early and the appropriate treatment of agranulocytosis resulted in complete recovery in both cases...
  6. ncbi The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 6:210-20. 2004
    ....
  7. ncbi [About the curability of schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:39-42. 2005
    ..His compliance has been perfect, clozapine has no side effects...
  8. ncbi Comparison between genes of Alzheimer's disease and brain tissue of others
    Peter Gaszner
    National Institute of Neurology and Psychiatry, Budapest, Hungary
    Neuropsychopharmacol Hung 8:211-4. 2006
    ..Silver staining was performed on some samples and 5 of 7 samples tested from one donor diagnosed with Alzheimer's like dementia showed evidence of Alzheimer's disease by this method...
  9. ncbi About the menopausal depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 7:208-14. 2005
    ..CONCLUSIONS: The combination of antidepressant and psychotherapy the best solution for the treatment of menopausal depression, but the therapy must be individual...
  10. ncbi [Pharmacovigilance as new direction of research]
    Gabor Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:194-8. 2005
    ..We review how the danger of polypharmacy can be avoided by reducing the dose of the current drug; by using therapeutic drug; or just by monitoring therapeutic and adverse effects...